Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALT0135
- Development stage
- Preclinical
- Lead developer
- Alturos Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ALT0135 is an orally bioavailable, brain-penetrant small molecule lead candidate developed by Alturos Therapeutics for the treatment of Alzheimer's Disease. Currently in the IND/CTA-enabling stage, the compound is designed to address the underlying pathology of neurodegeneration. ALT0135 is part of a pipeline focused on modulating neuroinflammatory pathways and restoring homeostatic functions in the central nervous system. Based on the company's patent portfolio and therapeutic focus, the drug is identified as an inhibitor of p38 alpha mitogen-activated protein kinase (MAPK), a target implicated in the neuroinflammatory response and synaptic dysfunction associated with Alzheimer's pathology.
- Other names
- ALT-0135ALT0135ALT 0135
Beyond the preview
Go deeper on ALT0135.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALT0135.